ILF3 and gastric cancer: Thereby, these data supported that ILF3 acted as a tumor promoter and served as a potential new target for the use of statins to treat GC patients, and ILF3 elimination is a significant target to prevent and intervent GC, providing rationale for the use of statins to treat GC.